FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108258946> ?p ?o ?g. }

• W2108258946 endingPage "128" @default.
• W2108258946 startingPage "122" @default.
• W2108258946 abstract "This randomized, double-blind, double-dummy, multicenter trial assessed safety and efficacy of a single dose of IV zoledronic acid (ZOL) 5 mg vs. oral alendronate (ALN) 70 mg weekly in postmenopausal women with low bone mineral density (BMD) who had previously been treated with ALN. Postmenopausal women who were receiving oral ALN for at least 1 year immediately prior to randomization and with lumbar spine or femoral neck BMD T-score values ≤ − 2.0 prior to initiation of ALN were randomized to one 15-min IV infusion of ZOL 5 mg plus 52 weeks of oral placebo (n = 113) or one IV infusion of placebo plus 52 weeks of oral ALN 70 mg (n = 112). End points included percent change in lumbar spine BMD from baseline to month 12 and relative change from baseline in urine N-telopeptide of type I collagen (NTX), serum C-telopeptide of type I collagen (CTX), amino terminal propeptides of type I collagen (PINP), and bone-specific alkaline phosphatase (bone ALP) over 12 months. Adverse events, bone histomorphometry and microscopic appearance, and patient preference for the 2 treatment regimens were also assessed. In this study, a single infusion of ZOL 5 mg maintained BMD 12 months following the switch from oral ALN in women with osteoporosis. The mean duration of prior ALN therapy at baseline was 4 years. Mean biomarker levels in the ALN 70-mg group remained at or close to baseline levels for the duration of the study. In the ZOL 5-mg group, mean biomarker levels were reduced from baseline after 3 months, returned to baseline after 6 months, and increased thereafter but remained within the premenopausal range. The overall rates of adverse events were comparable in the 2 groups (ZOL 5 mg, 86.7%; ALN 70 mg, 80.4%). Headache occurred more commonly within the first 3 days after infusion with ZOL 5 mg (12.4%) than with ALN 70 mg (6.3%). Bone biopsies indicate that both treatments decrease excessive remodeling seen in osteoporosis. The majority (78.7%) of patients expressed preference for once yearly infusion over weekly oral therapy. We conclude that patients can be switched from oral ALN to ZOL 5 mg infusion with maintenance of therapeutic effect for at least 12 months and that patients prefer a once yearly infusion to weekly oral therapy." @default.
• W2108258946 created "2016-06-24" @default.
• W2108258946 creator A5007954572 @default.
• W2108258946 creator A5018463564 @default.
• W2108258946 creator A5030361963 @default.
• W2108258946 creator A5037453831 @default.
• W2108258946 creator A5043275961 @default.
• W2108258946 creator A5048725197 @default.
• W2108258946 creator A5052478195 @default.
• W2108258946 creator A5059209505 @default.
• W2108258946 creator A5062070063 @default.
• W2108258946 date "2007-07-01" @default.
• W2108258946 modified "2023-10-11" @default.
• W2108258946 title "Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate" @default.
• W2108258946 cites W1971365252 @default.
• W2108258946 cites W1978228601 @default.
• W2108258946 cites W1985327136 @default.
• W2108258946 cites W1990771263 @default.
• W2108258946 cites W1992637537 @default.
• W2108258946 cites W2057332307 @default.
• W2108258946 cites W2074890088 @default.
• W2108258946 cites W2108275539 @default.
• W2108258946 cites W2123171945 @default.
• W2108258946 cites W2152063648 @default.
• W2108258946 cites W2152412969 @default.
• W2108258946 cites W2167515284 @default.
• W2108258946 doi "https://doi.org/10.1016/j.bone.2007.03.011" @default.
• W2108258946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17468062" @default.
• W2108258946 hasPublicationYear "2007" @default.
• W2108258946 type Work @default.
• W2108258946 sameAs 2108258946 @default.
• W2108258946 citedByCount "155" @default.
• W2108258946 countsByYear W21082589462012 @default.
• W2108258946 countsByYear W21082589462013 @default.
• W2108258946 countsByYear W21082589462014 @default.
• W2108258946 countsByYear W21082589462015 @default.
• W2108258946 countsByYear W21082589462016 @default.
• W2108258946 countsByYear W21082589462017 @default.
• W2108258946 countsByYear W21082589462018 @default.
• W2108258946 countsByYear W21082589462019 @default.
• W2108258946 countsByYear W21082589462020 @default.
• W2108258946 countsByYear W21082589462021 @default.
• W2108258946 countsByYear W21082589462022 @default.
• W2108258946 countsByYear W21082589462023 @default.
• W2108258946 crossrefType "journal-article" @default.
• W2108258946 hasAuthorship W2108258946A5007954572 @default.
• W2108258946 hasAuthorship W2108258946A5018463564 @default.
• W2108258946 hasAuthorship W2108258946A5030361963 @default.
• W2108258946 hasAuthorship W2108258946A5037453831 @default.
• W2108258946 hasAuthorship W2108258946A5043275961 @default.
• W2108258946 hasAuthorship W2108258946A5048725197 @default.
• W2108258946 hasAuthorship W2108258946A5052478195 @default.
• W2108258946 hasAuthorship W2108258946A5059209505 @default.
• W2108258946 hasAuthorship W2108258946A5062070063 @default.
• W2108258946 hasConcept C125870589 @default.
• W2108258946 hasConcept C126322002 @default.
• W2108258946 hasConcept C126894567 @default.
• W2108258946 hasConcept C131075544 @default.
• W2108258946 hasConcept C134018914 @default.
• W2108258946 hasConcept C142724271 @default.
• W2108258946 hasConcept C160160445 @default.
• W2108258946 hasConcept C168563851 @default.
• W2108258946 hasConcept C170033053 @default.
• W2108258946 hasConcept C181199279 @default.
• W2108258946 hasConcept C185592680 @default.
• W2108258946 hasConcept C197934379 @default.
• W2108258946 hasConcept C204243189 @default.
• W2108258946 hasConcept C204787440 @default.
• W2108258946 hasConcept C27081682 @default.
• W2108258946 hasConcept C2775854910 @default.
• W2108258946 hasConcept C2776326535 @default.
• W2108258946 hasConcept C2776541429 @default.
• W2108258946 hasConcept C2776886416 @default.
• W2108258946 hasConcept C2779329777 @default.
• W2108258946 hasConcept C55493867 @default.
• W2108258946 hasConcept C71924100 @default.
• W2108258946 hasConcept C90924648 @default.
• W2108258946 hasConceptScore W2108258946C125870589 @default.
• W2108258946 hasConceptScore W2108258946C126322002 @default.
• W2108258946 hasConceptScore W2108258946C126894567 @default.
• W2108258946 hasConceptScore W2108258946C131075544 @default.
• W2108258946 hasConceptScore W2108258946C134018914 @default.
• W2108258946 hasConceptScore W2108258946C142724271 @default.
• W2108258946 hasConceptScore W2108258946C160160445 @default.
• W2108258946 hasConceptScore W2108258946C168563851 @default.
• W2108258946 hasConceptScore W2108258946C170033053 @default.
• W2108258946 hasConceptScore W2108258946C181199279 @default.
• W2108258946 hasConceptScore W2108258946C185592680 @default.
• W2108258946 hasConceptScore W2108258946C197934379 @default.
• W2108258946 hasConceptScore W2108258946C204243189 @default.
• W2108258946 hasConceptScore W2108258946C204787440 @default.
• W2108258946 hasConceptScore W2108258946C27081682 @default.
• W2108258946 hasConceptScore W2108258946C2775854910 @default.
• W2108258946 hasConceptScore W2108258946C2776326535 @default.
• W2108258946 hasConceptScore W2108258946C2776541429 @default.
• W2108258946 hasConceptScore W2108258946C2776886416 @default.
• W2108258946 hasConceptScore W2108258946C2779329777 @default.
• W2108258946 hasConceptScore W2108258946C55493867 @default.

• next